Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies

Journal of Oncology

Volumn , Issue , 2010, Pages

  Tzankov, Alexandar ^b   Medinger, Michael ^a   Fischer, Natalie ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FLUDARABINE; IDARUBICIN; IMATINIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; PLACEBO; PREDNISONE; THALIDOMIDE; TOPOTECAN; VASCULOTROPIN; VATALANIB;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CORNEA NEOVASCULARIZATION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPHONIA; FATIGUE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; LARGE CELL LYMPHOMA; LETHARGY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN FUNCTION; RASH; REVIEW; SOLID TUMOR; T CELL LYMPHOMA; THROMBOSIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77953520737     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/729725     Document Type: Review

References (140)

1. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine 1995 1 1 27 31
2. Folkman J., Tumor angiogenesis: therapeutic implications The New England Journal of Medicine 1971 285 21 1182 1186
3. Lyden D., Hattori K., Dias S., Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nature Medicine 2001 7 11 1194 1201
4. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B., Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Reviews Cancer 2002 2 11 826 835
5. Peters B. A., Diaz L. A. Jr., Polyak K., Contribution of bone marrow-derived endothelial cells to human tumor vasculature Nature Medicine 2005 11 3 261 262
6. Shweiki D., Itin A., Soffer D., Keshet E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 1992 359 6398 843 845
7. Dor Y., Porat R., Keshet E., Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis American Journal of Physiology 2001 280 6 C1367 C1374
8. Ryuto M., Ono M., Izumi H., Induction of vascular endothelial growth factor by tumor necrosis factor in human glioma cells: possible roles of SP-1 Journal of Biological Chemistry 1996 271 45 28220 28228
9. Pertovaara L., Kaipainen A., Mustonen T., Vascular endothelial growth factor is induced in response to transforming growth factor- in fibroblastic and epithelial cells Journal of Biological Chemistry 1994 269 9 6271 6274
10. Kaelin W. G. Jr., The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma Clinical Cancer Research 2007 13 2 680s 682s
11. Dong X., Han Z. C., Yang R., Angiogenesis and antiangiogenic therapy in hematologic malignancies Critical Reviews in Oncology/Hematology 2007 62 2 105 118
12. Frater J. L., Kay N. E., Goolsby C. L., Crawford S. E., Dewald G. W., Peterson L. C., Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence Diagnostic Pathology 2008 3 1, article 16
13. Ferrara N., Gerber H.-P., LeCouter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676
14. Gille H., Kowalski J., Li B., Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants Journal of Biological Chemistry 2001 276 5 3222 3230
15. Hattori K., Dias S., Heissig B., Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells Journal of Experimental Medicine 2001 193 9 1005 1014
16. Bellamy W. T., Richter L., Frutiger Y., Grogan T. M., Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies Cancer Research 1999 59 3 728 733
17. Gill M., Dias S., Hattori K., Vascular trauma induces rapid but transient mobilization of VEGFR2+AC133+ endothelial precursor cells Circulation Research 2001 88 2 167 174
18. Casella I., Feccia T., Chelucci C., Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor Blood 2003 101 4 1316 1323
19. Autiero M., Luttun A., Tjwa M., Carmeliet P., Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders Journal of Thrombosis and Haemostasis 2003 1 7 1356 1370
20. Kim K. J., Li B., Winer J., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 1993 362 6423 841 844
21. Risau W., Mechanisms of angiogenesis Nature 1997 386 6626 671 674
22. Benouchan M., Colombo B. M., Anti-angiogenic strategies for cancer therapy International Journal of Oncology 2005 27 2 563 571
23. Hurwitz H., Fehrenbacher L., Novotny W., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer The New England Journal of Medicine 2004 350 23 2335 2342
24. Sandler A., Gray R., Perry M. C., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer The New England Journal of Medicine 2006 355 24 2542 2550
25. Miller K., Wang M., Gralow J., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer The New England Journal of Medicine 2007 357 26 2666 2676
26. Karp J. E., Gojo I., Pili R., Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1- -D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab Clinical Cancer Research 2004 10 11 3577 3585
27. Escudier B., Eisen T., Stadler W. M., Sorafenib in advanced clear-cell renal-cell carcinoma The New England Journal of Medicine 2007 356 2 125 134
28. Motzer R. J., Hutson T. E., Tomczak P., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma The New England Journal of Medicine 2007 356 2 115 124
29. Aguayo A., The role of angiogenesis in the biology and therapy of myelodysplastic syndromes Current Hematology Reports 2004 3 3 184 191
30. Medinger M., Skoda R., Gratwohl A., Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status British Journal of Haematology 2009 146 2 150 157
31. Padr T., Ruiz S., Bieker R., Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia Blood 2000 95 8 2637 2644
32. Pruneri G., Bertolini F., Soligo D., Angiogenesis in myelodysplastic syndromes British Journal of Cancer 1999 81 8 1398 1401
33. Steurer M., Zoller H., Augustin F., Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor Human Pathology 2007 38 7 1057 1064
34. Stifter G., Heiss S., Gastl G., Tzankov A., Stauder R., Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis European Journal of Haematology 2005 75 6 485 491
35. Tzankov A., Heiss S., Ebner S., Angiogenesis in nodal B cell lymphomas: a high throughput study Journal of Clinical Pathology 2007 60 5 476 482
36. Vacca A., Ribatti D., Roncali L., Bone marrow angiogenesis and progression in multiple myeloma British Journal of Haematology 1994 87 3 503 508
37. Majka M., Janowska-Wieczorek A., Ratajczak J., Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner Blood 2001 97 10 3075 3085
38. Dias S., Hattori K., Heissig B., Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias Proceedings of the National Academy of Sciences of the United States of America 2001 98 19 10857 10862
39. Loges S., Heil G., Bruweleit M., Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival Journal of Clinical Oncology 2005 23 6 1109 1117
40. Leung D. W., Cachianes G., Kuang W.-J., Goeddel D. V., Ferrara N., Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 246 4935 1306 1309
41. Perez-Atayde A. R., Sallan S. E., Tedrow U., Connors S., Allred E., Folkman J., Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia American Journal of Pathology 1997 150 3 815 821
42. Yetgin S., Yenicesu I., etin M., Tuncer M., Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia Leukemia Lymphoma 2001 42 1-2 83 88
43. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364
44. Norn-Nystrm U., Heyman M., Frisk P., Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome British Journal of Haematology 2009 146 5 521 530
45. Aguayo A., Kantarjian H. M., Estey E. H., Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes Cancer 2002 95 9 1923 1930
46. Aguayo A., Estey E., Kantarjian H., Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia Blood 1999 94 11 3717 3721
47. Fiedler W., Graeven U., Ergn S., Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia Blood 1997 89 6 1870 1875
48. Chen H., Treweeke A. T., West D. C., In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells Blood 2000 96 9 3181 3187
49. Dias S., Hattori K., Zhu Z., Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration Journal of Clinical Investigation 2000 106 4 511 521
50. Hu Q., Dey A. L., Yang Y., Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes Cancer 2004 100 9 1884 1891
51. Lai R., Estey E., Shen Y., Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome Cancer 2002 94 1 14 17
52. Bellamy W. T., Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies Seminars in Oncology 2001 28 6 551 559
53. Allouche M., Bayard F., Clamens S., Fillola G., Sie P., Amalric F., Expression of basic fibroblast growth factor (bFGF) and FCF-receptors in human leukemic cells Leukemia 1995 9 1 77 86
54. Gerber H.-P., Malik A. K., Solar G. P., VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism Nature 2002 417 6892 954 958
55. Presta L. G., Chen H., O'Connor S. J., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Research 1997 57 20 4593 4599
56. Moncada B., Baranda M. L., Gonzlez-Amaro R., Urbina R., Loredo C. E., Thalidomideeffect on T cell subsets as a possible mechanism of action International Journal of Leprosy 1985 53 2 201 205
57. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085
58. Gupta D., Treon S. P., Shima Y., Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 2001 15 12 1950 1961
59. Teo S. K., Properties of thalidomide and its analogues: implications for anticancer therapy AAPS Journal 2005 7 1 E14 E19
60. Dredge K., Marriott J. B., Macdonald C. D., Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects British Journal of Cancer 2002 87 10 1166 1172
61. Thomas D. A., Estey E., Giles F. J., Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia British Journal of Haematology 2003 123 3 436 441
62. Steins M. B., Padr T., Bieker R., Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood 2002 99 3 834 839
63. Barr P., Fu P., Lazarus H., Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia Leukemia Lymphoma 2007 48 10 1940 1949
64. Drevs J., Mller-Driver R., Wittig C., PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging Cancer Research 2002 62 14 4015 4022
65. Mross K., Drevs J., Mller M., Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours European Journal of Cancer 2005 41 9 1291 1299
66. Wood J. M., Bold G., Buchdunger E., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Research 2000 60 8 2178 2189
67. Lin B., Podar K., Gupta D., The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment Cancer Research 2002 62 17 5019 5026
68. Roboz G. J., Giles F. J., List A. F., Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome Leukemia 2006 20 6 952 957
69. Barbarroja N., Torres L. A., Luque M. J., Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia Experimental Hematology 2009 37 6 679 691
70. Wedge S. R., Kendrew J., Hennequin L. F., AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Research 2005 65 10 4389 4400
71. Drevs J., Siegert P., Medinger M., Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors Journal of Clinical Oncology 2007 25 21 3045 3054
72. Fiedler W., Mesters R., Heuser M., An open-label, phase I study of cediranib (RECENTINTM) in patients with acute myeloid leukemia Leukemia Research 2010 34 2 196 202
73. Brunner B., Gunsilius E., Schumacher P., Zwierzina H., Gastl G., Stauder R., Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia Journal of Hematotherapy and Stem Cell Research 2002 11 1 119 125
74. Wimazal F., Krauth M.-T., Vales A., Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category Leukemia Lymphoma 2006 47 3 451 460
75. Musto P., Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives Leukemia Research 2004 28 4 325 332
76. Raza A., Mehdi M., Mumtaz M., Ali F., Lascher S., Galili N., Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia Cancer 2008 113 7 1596 1604
77. Kotla V., Goel S., Nischal S., Mechanism of action of lenalidomide in hematological malignancies Journal of Hematology and Oncology 2009 2, article 36
78. List A., Dewald G., Bennett J., Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion The New England Journal of Medicine 2006 355 14 1456 1465
79. Roccaro A. M., Hideshima T., Raje N., Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Research 2006 66 1 184 191
80. Sezer O., Niemller K., Eucker J., Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma Annals of Hematology 2000 79 10 574 577
81. Rajkumar S. V., Leong T., Roche P. C., Prognostic value of bone marrow angiogenesis in multiple myeloma Clinical Cancer Research 2000 6 8 3111 3116
82. Munshi N. C., Wilson C., Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis Seminars in Oncology 2001 28 6 565 569
83. Kumar S., Witzig T. E., Timm M., Expression of VEGF and its receptors by myeloma cells Leukemia 2003 17 10 2025 2031
84. Podar K., Tai Y.-T., Davies F. E., Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 2001 98 2 428 435
85. Dankbar B., Padr T., Leo R., Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood 2000 95 8 2630 2636
86. Rajkumar S. V., Mesa R. A., Tefferi A., A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies Journal of Hematotherapy and Stem Cell Research 2002 11 1 33 47
87. Kumar S., Witzig T. E., Timm M., Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression Blood 2004 104 4 1159 1165
88. Pour L., Svachova H., Adam Z., Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response Annals of Hematology 2010 89 4 385 389
89. Singhal S., Mehta J., Desikan R., Antitumor activity of thalidomide in refractory multiple myeloma The New England Journal of Medicine 1999 341 21 1565 1571
90. Barlogie B., Desikan R., Eddlemon P., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 2001 98 2 492 494
91. Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R., Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2006 24 3 431 436
92. Dimopoulos M., Spencer A., Attal M., Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma The New England Journal of Medicine 2007 357 21 2123 2132
93. Weber D. M., Chen C., Niesvizky R., Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America The New England Journal of Medicine 2007 357 21 2133 2142
94. Lundberg L. G., Lerner R., Sundelin P., Rogers R., Folkman J., Palmblad J., Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity American Journal of Pathology 2000 157 1 15 19
95. Zetterberg E., Lundberg L. G., Palmblad J., Characterization of blood vessels in bone marrow from patients with chronic myeloid leukemia and polycythemia vera Scandinavian Journal of Clinical and Laboratory Investigation 2004 64 7 641 647
96. Wrbel T., Mazur G., Surowiak P., Woowiec D., Jele M., Kuliczkowski K., Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD) Pathology and Oncology Research 2003 9 3 170 173 (Pubitemid 37429496)
97. Ponzoni M., Savage D. G., Ferreri A. J. M., Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining Modern Pathology 2004 17 12 1513 1520
98. Kralovics R., Passamonti F., Buser A. S., A gain-of-function mutation of JAK2 in myeloproliferative disorders The New England Journal of Medicine 2005 352 17 1779 1790 (Pubitemid 40570926)
99. Kralovics R., Teo S.-S., Li S., Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Blood 2006 108 4 1377 1380
100. Boveri E., Passamonti F., Rumi E., Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations British Journal of Haematology 2008 140 2 162 168
101. Gianelli U., Vener C., Raviele P. R., VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders American Journal of Clinical Pathology 2007 128 6 966 973
102. Zhu K., Amin M. A., Zha Y., Harlow L. A., Koch A. E., Mechanism by which H-2g, a glucose analog of blood group H antigen, mediates angiogenesis Blood 2005 105 6 2343 2349
103. Dudley A. C., Thomas D., Best J., Jenkins A., A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia Biochemical Journal 2005 390 2 427 436
104. Sozer S., Fiel M. I., Schiano T., Xu M., Mascarenhas J., Hoffman R., The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome Blood 2009 113 21 5246 5249
105. Thomas D. A., Giles F. J., Albitar M., Thalidomide therapy for myelofibrosis with myeloid metaplasia Cancer 2006 106 9 1974 1984
106. Abgrall J.-F., Guibaud I., Bastie J.-N., Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study Haematologica 2006 91 8 1027 1032
107. Tefferi A., Cortes J., Verstovsek S., Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood 2006 108 4 1158 1164 (Pubitemid 44232010)
108. Quints-Cardama A., Kantarjian H. M., Manshouri T., Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis Journal of Clinical Oncology 2009 27 28 4760 4766
109. Giles F. J., List A. F., Carroll M., PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia Leukemia Research 2007 31 7 891 897
110. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L., Dammacco F., Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study European Journal of Haematology 1996 56 1-2 45 53 (Pubitemid 26075594)
111. Vacca A., Ribatti D., Ruco L., Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas British Journal of Cancer 1999 79 5-6 965 970
112. Arias V., Soares F. A., Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study Leukemia Lymphoma 2001 40 1-2 157 166
113. Koster A., Raemaekers J. M. M., Angiogenesis in malignant lymphoma Current Opinion in Oncology 2005 17 6 611 616
114. Vacca A., Moretti S., Ribatti D., Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9 European Journal of Cancer 1997 33 10 1685 1692
115. Schaerer L., Schmid M. H., Mueller B., Dummer R. G., Burg G., Kempf W., Angiogenesis in cutaneous lymphoproliferative disorders. Microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas American Journal of Dermatopathology 2000 22 2 140 143
116. Mazur G., Woniak Z., Wrbel T., Maj J., Kuliczkowski K., Increased angiogenesis in cutaneous T-cell lymphomas Pathology and Oncology Research 2004 10 1 34 36
117. Passalidou E., Stewart M., Trivella M., Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma British Journal of Cancer 2003 88 4 553 559
118. Streubel B., Chott A., Huber D., Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas The New England Journal of Medicine 2004 351 3 250 259
119. Ruan J., Hajjar K., Rafii S., Leonard J. P., Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma Annals of Oncology 2009 20 3 413 424
120. Dave S. S., Wright G., Tan B., Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells The New England Journal of Medicine 2004 351 21 2159 2169
121. Lenz G., Wright G., Dave S. S., Stromal gene signatures in large-B-cell lymphomas The New England Journal of Medicine 2008 359 22 2313 2323
122. Ho C.-L., Sheu L.-F., Li C.-Y., Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma Applied Immunohistochemistry and Molecular Morphology 2002 10 4 316 321
123. Salven P., Orpana A., Teerenhovi L., Joensuu H., Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood 2000 96 12 3712 3718
124. Gratzinger D., Zhao S., Tibshirani R. J., Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy Laboratory Investigation 2008 88 1 38 47
125. Jrgensen J. M., Srensen F. B., Bendix K., Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes Leukemia Lymphoma 2007 48 3 584 595
126. Zhao W.-L., Mourah S., Mounier N., Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression Laboratory Investigation 2004 84 11 1512 1519
127. Doussis-Anagnostopoulou I. A., Talks K. L., Turley H., Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease Journal of Pathology 2002 197 5 677 683
128. Mainou-Fowler T., Angus B., Miller S., Proctor S. J., Taylor P. R. A., Wood K. M., Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL) Leukemia Lymphoma 2006 47 2 223 230
129. Stopeck A. T., Unger J. M., Rimsza L. M., A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108 Leukemia Lymphoma 2009 50 5 728 735
130. Pro B., Younes A., Albitar M., Thalidomide for patients with recurrent lymphoma Cancer 2004 100 6 1186 1189
131. Wiernik P. H., Lossos I. S., Tuscano J. M., Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma Journal of Clinical Oncology 2008 26 30 4952 4957
132. Witzig T. E., Wiernik P. H., Moore T., Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 2009 27 32 5404 5409
133. Bruns I., Fox F., Reinecke P., Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab Leukemia 2005 19 11 1993 1995
134. Aguiar Bujanda D., Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab Annals of Oncology 2008 19 2 396 397
135. Ramasamy K., Lim Z., Pagliuca A., Salisbury J. R., Mufti G. J., Devereux S., Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone Haematologica 2006 91 supplement 8, article ECR44 117 118
136. Dogan A., Ngu L. S. P., Ng S. H., Cervi P. L., Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide Leukemia 2005 19 5 873 875
137. Strupp C., Aivado M., Germing U., Gattermann N., Haas R., Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports Leukemia Lymphoma 2002 43 1 133 137
138. Horwitz S. M., Novel therapies for cutaneous T-cell lymphomas Clinical Lymphoma Myeloma 2008 8 supplement 5 S187 S192
139. Reiners K. S., Gossmann A., von Strandmann E. P., Bll B., Engert A., Borchmann P., Effects of the anti-VEGF Monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed hodgkin lymphoma Journal of Immunotherapy 2009 32 5 508 512
140. Kuruvilla J., Song K., Mollee P., A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma Hematology 2006 11 1 25 29